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Abstract Early detection of colorectal cancer (CRC) is vital
for the improvement of disease prognosis. However to date
there are no blood-based biomarkers sensitive and specific
enough for early diagnosis. We analysed the differences in
serum protein expression of early stage CRC (Dukes’ A and
B) and late stage CRC (Dukes’ C and D) against normal con-
trols using 2D Fluorescence Difference Gel Electrophoresis
(2D-DIGE). Analysis of the 2D maps showed that 23 proteins
were differentially expressed between groups (p≤0.05) and
these proteins were identified with LC-MS/MS. Eight proteins
were up-regulated and 2 down-regulated in patients with early
CRC, whereas 14 proteins were up-regulated and 4 down-
regulated in those with late CRC compared to normal controls
(p≤0.05). Five proteins, namely apolipoprotein A1 (APOA1),
apolipoprotein E (APOE), complement factor H (CFH),
galectin-7 (GAL7) and synaptojanin-2 (SYNJ2) were validat-
ed using ELISA and only APOA1 and GAL-7 showed con-
sistent findings. Further validation using immunohistochem-
istry showed negative immunoreactivity for GAL-7 in CRC
tissues, suggesting that GAL-7 detected in the serum did not
originate from the CRC tumour. APOA1 showed positive
immunoreactivity but its expression did not correlate with
Dukes’ staging (p=0.314), tumour grading (p=0.880) and
lymph node involvement (p=0.108). Differences in APOA1
isoforms and/or conformation between serum and tissue sam-
ples as well as tumour heterogeneity may explain for the dis-
crepancies between DIGE and ELISAwhen compared to im-
munohistochemistry. Structural and functional studies of
APOA1 in future would best describe the role of APOA1 in
CRC.
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Introduction
Colorectal cancer (CRC) is the third most common cancer in
men and the second in women worldwide [1]. In Peninsular
Malaysia, it was ranked in 2006 as the most common cancer in
men (16.2 % of the total cancer cases) and the second most
common cancer in women (10.6 % of the total cancer cases)
[2]. CRC is curable when detected at an early stage. It was
reported that the 5-year survival rate is 90 % when CRC is
detected at an early, localized stage; however, only 39 % of
CRC are diagnosed at this stage due to the lack of specific and
sensitive screening tests for early detection and monitoring of
disease progression [3].
Current common screening tests for CRC include colonos-
copy, flexible sigmoidoscopy, fecal occult blood test (FOBT)
and double contrast barium enema [4]. Colonoscopy is the
gold standard for CRC screening with 97 % sensitivity and
98 % specificity. However, it is not applicable to the general
population due to its invasiveness, high cost, requires uncom-
fortable bowel preparation and highly trained medical person-
nel which leads to the reluctance of the general population at
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risk (>50 years) and those not at risk (<50 years) to go for this
screening test. The remaining screening tests are hampered by
their low sensitivities and specificities [5]. Hence, there
is an urgent need to identify more sensitive and specific
screening approaches which are less invasive and easy
to perform for the early detection of CRC where thera-
py is most likely to be effective.
The use of serum biomarkers to distinguish between those
with CRC and those without would be a useful tool in the
CRC mass screening program since serum is one of the most
accessible biological specimens which can be sampled. How-
ever, the serum also contains the widest dynamic range of
cellular proteins in the bodymaking it one of the most difficult
biological fluids to be studied due to its complex nature [6]. It
was reported that the serum proteome might reflect the health
status of every organ and tissue in the body since most of the
cells in the body are thought to leak and secrete proteins into
the serum [6].
Although there have been many serum-based proteomic
studies for CRC which have been published, none of the
CRC biomarkers reported in the literature have gained FDA
approval. Currently, the only protein biomarker which is clin-
ically in use for the detection of CRC is carcinoembryonic
antigen (CEA) [7]. However, it is not suitable as a screening
biomarker due to its low sensitivity, specificity and positive
predictive value [8]. It is widely used as a prognostic factor
and recurrence indicator of CRC [9]. Due to the highly het-
erogeneous nature of CRC, it is likely that a panel of bio-
markers instead of a single biomarker would be more effective
in the early detection of CRC.
ColonSentry™, the world’s first commercially available
blood-based test for CRC has exploited the multiple bio-
markers approach in which a seven-gene blood-based mRNA
biomarker panel is used to discriminate CRC [10, 11]. How-
ever the analysis of mRNA is not a direct reflection of the
functional protein content in the cells. Poor correlation be-
tween mRNA and protein expression levels was reported in
a previous finding [12] and it showed gene expression mea-
surement at the mRNA level might not be sufficient. At cel-
lular level, mRNA is subjected to post transcriptional
modifications such as alternative splicing and this will
result in functional alterations of the proteins. In addi-
tion, some mRNA might not be translated at all. Hence,
there is still a strong basis for searching for proteomic-
based biomarkers.
The aim of this study was to identify and validate potential
protein biomarkers in the serum of patients with CRC. We
used 2D Fluorescence Difference Gel Electrophoresis (2D-
DIGE) coupled with tandem mass spectrometry (LC-MS/
MS) and pathway analysis for identification of potential can-
didate protein biomarkers. These biomarkers were further val-




This study was approved by the Medical Ethics Committee of
the university and written informed consent was obtained
from the patients. Complete clinical and pathological reports
were obtained from the medical records.
Serum samples of newly diagnosed colorectal cancer pa-
tients from early stage (Dukes’ stage A and B) (n=37) and
advanced stage (Dukes’ stage C and D) (n=27) were collected
prior to surgery. Patients were recruited from 1st August 2008
until 31st July 2010. Newly diagnosed patients were identified
by their abnormal sigmoidoscopy or colonoscopy observation
and confirmed by biopsy results. A total of 24 CRC adeno-
carcinoma serum samples were then selected randomly from
the pool of patients and consisted of 8 each in the early stage,
late stage and normal controls groups. Normal control subjects
(n=26) were recruited from the endoscopy clinic and these
were patients who underwent colonoscopy and presented with
benign colonic disease which included diverticular disease
(diverticulosis and diverticulitis), colonic constipation and al-
tered bowel habits. Patients who presented with polyps and
ulcerative colitis were excluded from this study.
For the validation using immunohistochemistry, a total of
96 formalin-fixed paraffin embedded tissues (FFPE) of CRC
patients from the years of 2005 to 2009 were retrieved from
the Histopathology Unit, Department of Pathology. These
cases included Dukes’ stage A (n=2), Dukes’ stage B (n=
48), Dukes’ stage C (n=37) and Dukes’ stage D (n=9). The
age of the patients ranged from 38 to 87 years (mean age,
65 years). Slides stained with haematoxylin and eosin were
reviewed by a pathologist and a FFPE block with representa-
tive tumour was selected from each case for tissue sectioning.
Serum Protein Enrichment
One mL of serum with estimated protein concentration of
≥50 mg/mL was used for protein enrichment by the
ProteoMiner™ Protein Enrichment kit (BioRad, USA).
Sample clean-up was then performed on the enriched sam-
ples by using the ReadyPrep™ 2D clean-up kit (Biorad, USA)
as per manufacturer’s protocols. The precipitated proteins
were washed and resuspended in DIGE lysis buffer (9M urea,
4 %CHAPS, 30mM tris). The pH of the resuspended samples
was adjusted between pH 8-9 by lysis buffer pH 11 prior to the
CyDye labeling.
Cy™Dye DIGE Fluor Minimal Labeling
After the enrichment, cleaning up and pH adjustment, the
serum samples were labeled with the CyDyes (GE Healthcare,
Uppsala, Sweden). A total of 5 nmol dry CyDye was
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reconstituted with 5 μL of anhydrous dimethylformamide
(DMF) (Sigma Aldrich, USA). CyDye working solution
(400 pmol/μL) was prepared by mixing the CyDye stock so-
lution and DMF at 2:3 ratio. The samples were randomly
labeled with the CyDye working solutions (Cy3 or Cy5) at a
ratio of 400 pmol to 50 μg of proteins and were incubated for
30min on ice. Cy2 was used to label a pooled sample (internal
standard) which comprised of an equal amount of proteins
from all samples. This was followed by quenching of the
CyDye labeling activities by adding 1μL of 10mmol/L lysine
to 50 μg of proteins for 10 min on ice. All procedures above
were carried out in the dark.
2D Fluorescence Difference Gel Electrophoresis
(2D-DIGE)
An equal volume of 2X sample buffer (8 M urea, 2 % IPG
buffer, 130 mM dithiothreitol (DTT), 4 % CHAPS) were
added to the pooled Cy2, Cy3 and Cy5 labeled samples
(50 μg protein each) and were incubated for 10 min on ice
in the dark. Rehydration buffer (8 M urea, 2 % CHAPS, 2 %
IPG buffer, 20 mM DTT) was added to the samples to
achieved a final volume of 340 μl. Samples were rehydrated
overnight on 18 cm, pH 4-7 L Immobiline Drystrip gels and
IEF was performed at 20 °Cwith a current limit of 50 μA/strip
in the dark under the following conditions: step and hold for
2 h at 500 V, linear gradient for 3 h at 3500 V, 8000 V linear
gradient to 15000 Vhrs, step and hold at 8000 V to 100,000
Vhrs for a total of 100 kVh. After first dimension separation
based on proteins pI, the focused IPG strips were equilibrated
with equilibration buffer I (6 M urea, 50 mM Tris–HCl
pH 8.8, 30 % glycerol, 2 % SDS, 80 mM DTT) and equili-
bration buffer II (6 M urea, 50 mM Tris–HCl pH 8.8, 30 %
glycerol, 2 % SDS, 169 mM IAA) for 15 min respectively
before second dimension separation on a 1 mm-thick-10 %
resolving gel. Gels were then visualized by using Ettan DIGE
Imager (GE Healthcare) and then analyzed by ImageMaster
2D Platinum ver. 7.0, DeCyder 2D ver. 6.5 and DeCyder
Extended Data Analysis (EDA) software (GE Healthcare).
Protein identification by mass spectrometer
Gels were silver stained and the spots of interest were
selected for trypsin digestion. Gel pieces were washed
with 100 mM ammonium bicarbonate for 10 min. After
washing, the gels were destained twice in solution contain-
ing 15 mM potassium ferricyanide and 50 mM sodium
thiosulphate for 15 min each. Proteins were then reduced
in 10 mM DTT in 100 mM ammonium bicarbonate for
30 min at 60 °C. The reduced proteins were then
alkylated in 55 mM IAA in 100 mM ammonium bicar-
bonate for 20 min in the dark. Gels were washed with
50 % acetonitrile in 100 mM ammonium bicarbonate for 3
times, 20 min each. Gels were dried in speed vacuum for
15 min after the dehydration step with 100 % acetonitrile
for 15 min. For protein digestion, 7 ng/μl trypsin solution
was added and incubated at 37 °C overnight. Peptides
were extracted with 50 and 100 % acetonitrile. Dried ex-
tract was reconstituted with 0.1 % formic acid solution
and injected into the NanoACQUITY UPLC Q-TOF mass
spectrometer (MS). MS was programmed to step between
normal (5 eV) and elevated (25 to 40 eV) collision ener-
gies on the gas cell, using a scan time of 1.5 seconds per
function over 50 to 1990 m/z. The ProteinLynx Global
server (Waters, USA) was used as the search engine
against human database Human and Enolase-1.0. Proteins
identified were then subjected to pathway analysis by In-
genuity Pathway Analysis (IPA) software (California,
USA).
Candidate biomarkers were selected from the list of differ-
entially expressed proteins for validation with ELISAmethod.
The selection criteria for these five biomarkers were based on:
(1) protein functions which showed possible involvement in
the CRC/cancer pathways from the literature review; (2) se-
quence coverage obtained by mass spectrometer with a value
of ≥15 % (Table 1).
ELISAValidation
A total of 66 serum samples which comprised of 29 early
stages of CRC, 19 late stages of CRC and 18 normal controls
were selected for ELISA validation. Human apolipoprotein
A1 (APOA1), apolipoprotein E (APOE), complement factor
H (CFH), synaptojanin-2 (SYNJ2) and galectin-7 (GAL7)
were validated using ELISA kits (Cusabio Biotech, USA)
according to the manufacturer’s protocols. Briefly, 100 μl of
standard, blank and samples were dispensed into the wells and
incubated for 2 h at 37 °C. A total of 100 μl biotin-antibody
working solution was added into each well and incubated for
1 h at 37 °C. One hundred μl of HRP-avidin working solution
was added to each well and incubated for 1 h at 37 °C. This
was followed by aspiration and washing for five times before
90 μl of TMB substrate added to each well and incubated for
30 min at 37 °C in the dark. Finally the reaction was stopped
with the addition of 50 μl stop solution into each well and
gently mixed for about 30 s. The microplate was then read at
450 nm within 30 min.
Immunohistochemistry
CRC tissues (4 μm thickness) were mounted on L-polylysine
slides. The sections were deparaffinized twice in Xylene and
subsequently rehydrated with ethanol sequentially in descend-
ing concentrations of 100, 90, 70 and 50 % respectively. The
sections were then washed before endogenous peroxidase
quenching by 3 % H2O2. The sections were treated using a
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target retrieval antigen buffer, pH 9.0 (Dako, USA) in a
decloaking chamber (pressure cooker) at 98 °C for 20 min.
The sections were then cooled down at room temperature for
20 min. Thereafter, sections were incubated with the diluted
primary antibody monoclonal mouse [12C8] anti-
apolipoprotein A1 (4 μg/mL) for 30 min. The sections were
then washed in TBS buffer 0.05 M, pH 7.6 for three times,
3 min each, and further incubated with secondary antibody
from Dako Envision kit for 30 min. Sections were washed
with TBS buffer 0.05M, pH 7.6 again for 3 times, 3 min each.
Sections were then developed for 8 min with high sensitivity
diaminobenzidine (DAB) chromogenic substrate (Dako RE-
AL™ Envision™ Detection System Peroxidase/DAB+, Rab-
bit/Mouse, Denmark) and counterstained with haematoxylin
(Haematoxylin Solution Modified acc to Gill III, Merck,
Germany). Finally, the sections were dehydrated sequentially
with ethanol with descending concentrations of 50, 70, 90 and
100% respectively. Sections were mounted with DPx (Merck,
Germany) before viewed under light microscope.
Statistical Analysis
Immunohistochemistry staining results were interpreted using
a 2-tier scoring system by considering the area extent of stain-
ing, according to the scoring method by Kim et al. [13]. Every
tumour was given a score according to the area extent of
cytoplasmic stained cells: <10 %=0; 10–50 %=1; >50 %=
2. Results were analyzed by SPSS ver. 15.0 using Chi-square
test. P-values less than 0.05 were considered as statistically
significant.















1 Q15113 Procollagen C endopeptidase
enhancer 1
19.4 47.9 7.3 Up Down* Proteolysis
2 Q53RT3 Human retroviral like aspartic
protease 1
9.3 37 5.1 Up Up* Proteolysis
3 Q9P173 Human PRO2275 21.7 13.1 9.6 Up Up* Proteolysis
4 P68871 Hemoglobin subunit beta 73.5 16 6.9 Up Up* Transport proteins
5 Q363Q5 Truncated beta globin fragment 72.5 4.5 10 Up* Down* Transport proteins
6 P02768 Albumin 12.9 45.1 5.7 Up* Up Transport proteins
7 P02649 Apolipoprotein E 42.1 19.9 8.7 Up Up* Transport proteins
8 P02647 Apolipoprotein A1 31.1 30.8 5.4 Up* Up* Transport proteins
9 P47929 Galectin-7 52.2 15.1 7.6 Down* Up Apoptosis
10 C9JSK2 Human uncharacterized protein
CFH
51.2 43.9 7.3 Up Up* Acute phase proteins
11 P08603 Complement factor H 32.1 31 7.7 Down Down Acute phase proteins
12 P0C0L4 Complement C4A 11.5 19.3 6.6 Up* Up Acute phase proteins
13 Q14624 Inter alpha trypsin inhibitor heavy
chain H4
5.05 103.3 6.5 Up Up* Acute phase proteins
14 P01009 Alpha 1-anti trypsin 11.1 34.7 4.9 Up Up* Acute phase proteins
15 P02735 Human serum amyloid 20.2 25.4 6.1 Up Up* Acute phase proteins
16 P04070 Human vitamin K dependent
protein C
21.7 52 5.8 Up Up* Coagulation factors
17 P00734 Human prothrombin 10 70 5.5 Up* Up* Coagulation factors
18 Q9GZN7 Protein rogdi homolog 12 32.2 8.3 Up* Up* Cellular proliferation
& differentiation
19 Q70YC5 Human isoform 6 of protein ZNF
365
43.1 5.7 11 Down* Down* Cellular proliferation
& differentiation
20 Q5SSB9 Ficolin collagen fibrinogen domain
containing 3 hakata protein
39.4 11.4 4.6 Up* Up Signal transduction
21 O15056 Synatojanin-2 17.4 10 4.7 Up* Up* Signal transduction
22 P04262 Keratin type II cytoskeletal I Down Down* Structural proteins
23 Human uncharacterized protein
LOC134121
9.5 17 7.5 Up Up* Unknown
*Statistically significant differences (p<0.05) when compared between different study groupss
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Results
A total of 2419 spots were detected by 2D-DIGE and 23
proteins (derived from 33 spots) were significantly differen-
tially expressed between study groups (p≤0.05) (Table 1). In
the early stage CRC group, 8 proteins were up-regulated (trun-
cated beta globin fragment, albumin, complement C4A, pro-
tein rogdi homolog, ficolin collagen fibrinogen domain con-
taining 3 Hakata antigen, prothrombin, SYNJ2 and APOA1)
and 2 proteins were down-regulated (GAL7 and isoform 6 of
protein ZNF365).
In late stage CRC group, 14 proteins were up-regulated
(hemoglobin subunit beta, human retroviral like aspartic pro-
tease 1, human uncharacterized protein CFH, human
PRO2275, human uncharacterized protein LOC134121,
APOE, human vitamin K dependent protein C, protein rogdi
homolog, inter-alpha-trypsin inhibitor heavy chain H4, alpha
1-antitrypsin, human serum amyloid, prothrombin, SYJN2
and APOA1) and 4 proteins were down-regulated
(PCOLCE1, truncated beta globin fragment, keratins and hu-
man isoform 6 of protein ZNF365) (Table 1).
The Ingenuity Pathways Analysis (IPA) revealed interac-
tion between 21 proteins. These proteins are involved in cel-
lular proteolysis, protein transport, apoptosis, acute phase re-
actions, coagulation factors, cellular proliferation and differ-
entiation, structural protein and signal transduction pathways
(Table 1).
The top canonical pathways which are associated with
CRC included liver X receptor/ retinoid X receptor (LXR/
RXR) activation, acute phase response signaling, clathrin-
mediated endocytosis signaling, blood coagulation and com-
plement system pathway. Of these pathways, the LXR/RXR
activation pathway is the most highly up-regulated pathway
which also involves APOA1 and APOE regulation. The net-
work is centered on TNF and ERK1/2 that regulate inflamma-
tory responses, apoptosis and cell survival. Our pathway map
showed the relationship between APOA1 and APOE with the
TNF which acted as the central mediator in this network. CFH
and GAL-7 were connected to TNF via IgG (Fig. 1). Hence,
these four proteins were selected for further validation. In
addition, SYJN2 was also chosen for further validation due
to its reported role as novel Rac1 effector that regulates
clathrin-mediated endocytosis pathway which plays a major
role in malignant transformation and invasion [14]. It was
reported that Rac1 activity is regulated by ERK-MAP kinase
signaling [15].
Validation by ELISA showed APOA1 expression which is
consistent with the DIGE findings both in normal controls
versus early CRC and normal controls versus late CRC
(Fig. 2a); whereas GAL-7 expression status was only compa-
rable in normal controls vs. early CRC (Fig. 2b).
APOA1 and GAL-7was further validated at the tissue level
using 96 FFPE blocks. Immunohistochemistry results showed
100 % negative immunoreactivity for GAL-7 in CRC tissues
(data not shown). For APOA1, positive cytoplasmic staining
was observed in 9 of 48 Dukes’ B, 12 of 37 Dukes’ C and 1 of
9 Dukes’ D (23 % of total CRC cases). Normal cells and
Dukes’ A tumor cells did not show immunoreactivity of
APOA1 (Fig. 3a). Specific cytoplasmic staining was observed
in the tumour glands (Fig. 3b). APOA1 immunostaining
showed no relationship between Dukes’ staging (χ2=4.86,
df=4, p=0.30), tumour grading (χ2=1.19, df=4, p=0.88)
and lymph node involvement (χ2=4.46, df=2, p=0.11).
Discussion
We have identified 23 proteins which were differentially
expressed between patients with colorectal cancer and those
without. Our IPA analysis showed interaction between the two
central mediators namely TNF and ERK1/2 (Fig. 1). The ERK
pathway is one of the MAP kinase pathways that are activated
by TNF and are mainly involved in regulation of cellular
proliferation, differentiation, survival, apoptosis and stress re-
sponses and its dysregulation is a common occurrence in can-
cers [16]. The relationship between SYJN2 and Rac1 which
were found to be regulated by ERK-MAP kinase signaling
made us select this potential biomarker for ELISA validation
[15]. SYJN2 is a novel Rac1 effector that is required for the
formation of lamellipodia and invadopodia, as well as for
tumour cell migration and invasion which makes it a novel
potential target for therapeutic intervention in malignant tu-
mours [17]. Lamellipodia and invadopodia are specialized
membrane structures that are thought to be involved in extra-
cellular matrix degradation.
In many cancers, IgG antibodies are produced that recog-
nized cancer cells, form immune complexes and leads to the
activation of the complement pathway [18]. CFH functions as
a key regulator of the alternative pathway of the complement
system [18]. The indirect interaction between IgG and GAL-7
from the network was based on a previous study which report-
ed that IgG decreased the transcription of GAL-7 gene [19]
via an unknown molecular mechanism [20]. We also selected
GAL-7 for validation because of the reported novel function
for GAL-7 in promoting tumorigenesis by upregulating
MMP-9 gene expression [20].
The results of DIGE and ELISAwere comparable in which
both showed downregulation of GAL-7 in early CRC as com-
pared to normal control and we investigated further GAL-7
expression at the tissue level. Galectins belongs to the family
of beta-galactoside-binding proteins that are known to exhibit
a pro-apoptotic function which is regulated through c-Jun N-
terminal kinase (JNK) activation and mitochondrial cyto-
chrome c release [21]. GAL-7 has also been reported to act
as a pro-tumour protein which may be involved in the induc-
tion of matrix metalloproteinase-9 (MMP-9), which in turn
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plays an important role in cancer progression and metastasis
[22, 23]. Our data showed GAL-7 to be down-regulated in
early CRC suggesting its role in pro-apoptotic function. How-
ever, investigation of GAL-7 in CRC FFPE tissues revealed
100 % negative immunoreactivity in colorectal cancer tissues
which implied that the GAL-7 detected in the serummight not
be originating from the tumour tissues.
Cancer is also a disease of inflammation [24]. Inflamma-
tion has been found to induce the acute phase reaction, leading
to multiple alterations in lipid and lipoprotein metabolism
which are often induced by pro-inflammatory cytokines such
as tumour necrosis factor (TNF) [25]. Cytokine-induced alter-
ation of lipid metabolism during the acute phase response is
achieved through the deregulation of type II nuclear hormone
receptors which included liver X receptor (LXR) that will
subsequently bind to DNA as obligate heterodimers with the
retinoid X receptor (RXR) [26]. The LXR/RXR activation
pathway plays an important role in regulating the gene tran-
scription of APOE and ABCA1 which is responsible for
APOA1 mediated cholesterol efflux [27, 28]. A previous
study found that activation of LXR was able to inhibit the
hedgehog signaling pathway which is an important regulator
of tumour formation and carcinogenesis [29].
Our study showed that APOA1 was upregulated in early
and late stage of CRC relative to normal controls both in
DIGE and ELISA analysis. APOA1 is the major apoprotein
constituent of high density lipoprotein (HDL) in plasma. The
protein promotes cholesterol efflux from tissues to the liver for
excretion and act as a cofactor for lecithin cholesterol acyl
transferase (LCAT) which is responsible for the formation of
most plasma cholesteryl esters. Besides its roles in the lipid
transport, a recent study revealed that APOA1 has an impor-
tant role in tumour invasion and metastasis in colonic adeno-
carcinoma [30]. There is one cohort study which showed the
pre-diagnostic concentrations of APOA1 to be inversely asso-
ciated with risk of colon cancer, but not rectal cancer [31]. One
of the possible discrepancies of this study from our result
could be due to the fact we include both colon and rectum
cases in the analysis and that we had a much smaller sample
size. Besides that, differences in the disease stage might have
contributed to the discrepancies as well. The trend of APOA1
expression may be different in the pre-diagnostic stages of
CRC as compared to post-diagnostic stages which generally
included advanced tumour stages. Previous studies have re-
ported similar observations as well where apolipoprotein CI
(APOCI) in pre-diagnostic serum of breast cancer patients
Fig. 1 Biological interaction network revealed by Ingenuity Pathway
Analysis. The network is revealed as circles (genes) and lines
(biological relationship). Solid lines indicate direct interaction, and
dotted lines indicate indirect interactions between the genes. Genes
highlighted in orange are the potential candidates chosen for further
validation
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were found upregulated [32] but in another study using post-
diagnostic serum samples, the upregulation was not observed
in the [33]. In addition, yet another cohort study found that the
biomarker panels discovered in diagnostic samples was not
successfully validated in pre-diagnostic samples [34]. The
molecular mechanisms of these differences need to be further
elucidated.
Over-expression of APOA1 has also been observed in
bladder cancer [35] and aggressive bladder transitional cell
carcinoma [36]. Genetic variations of APOA1 may also act
as a marker for the increased risk of breast cancer [37].
APOA1 is also part of the OVA1 test for ovarian cancer which
utilizes APOA1, transthyretin, transferin, CA-125 and β2-
microglobulin as the panel biomarkers [38].
In our study, further validation of the APOA1 at tissue level
showed immunoreactivity in a proportion of samples but it did
not show any relationship between Dukes’ staging, tumor
grading and lymph node involvement. From our observation,
the discrepancy in the results of DIGE and ELISA findings
with immunostaining could be contributed by two factors: (1)
differences in APOA1 isoforms and/or conformation between
serum and tissues sample; (2) pronounced tumour
heterogeneity.
APOA1 is the main protein component of HDL which is
primarily synthesized in the liver and intestine. HDL exists in
blood in two conformational forms: discoidal and spherical
[39]. It was reported that the conformation of APOA1 in dis-
coidal complexes is dependent on particle size and that these
conformations are substantially different from that of APOA1
on spherical complexes [39]. We postulate that lipid-free
APOA1 in the tissue might exist in different conformations
and that the differences in APOA1 conformation may be crit-
ical to the antibody binding during immunochemistry assay.
Hence, we postulate that this could explain the discrepancy
between 2D-DIGE and ELISA versus immunostaining.
Tumour heterogeneity is a general phenomenon in cancer
[40]. The tumour in colorectal cancer is often large and highly
Fig 2 Expression of GAL-7 and APOA1 in serum of CRC patients.
ELISA results shown by the boxplot. The spots for the respective
proteins are depicted above the boxplot
Fig 3 Immunohistochemistry staining of APOA1 in paraffin-embedded tissue of CRC. a Negative immunoreactivity in normal colonic cells (area
stained score 0, ×200); b Cytoplasmic staining at glandular structure of CRC FFPE (area stained score 1, ×200)
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heterogeneous with marked stromal areas between glandular
structures [41]. The conventional tumour sections resected for
FFPE block only represent a very small fraction of the volume
of most human tumours [42]. Hence it is possible that for
some of the samples the FFPE block used might not adequate-
ly represent the tumour of origin.
In conclusion, our study has identified serum APOA1 as
one of the potential biomarkers for CRC by showing consis-
tent results with using ELISA. APOA1 needs to be further
assessed structurally and functionally to provide more insight
into its role in CRC.
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